Influences of IL-6R antibody on PMMA bone cement-mediated expression of OPG and RANKL in synovial fibroblasts

Abstract

Effect of interleukin-6 receptor (IL-6R) antibody on polymethyl methacrylate (PMMA) bone cement-mediated expression of osteoprotegerin (OPG) and receptor activator of nuclear factor-kappaB ligand (RANKL) in synovial fibroblasts was investigated. Synovial tissue obtained from total knee arthroplasty was digested and cultured. Inverted microscope was employed to observe the synovial cells and immunocytochemistry (SABC method) staining was used to identify synovial fibroblasts. This experiment was divided into three groups according to different culture media: PMMA group (75 μg/mL PMMA bone cement particles), IL-6R antibody group (10 ng/mL IL-6R antibody+75 μg/mL PMMA bone cement particles), and control group (no IL-6R antibody or PMMA bone cement particles). Influence of IL-6R antibody and PMMA on proliferation of synovial fibroblasts was measured by cell counting kit-8 (CCK-8). ELISA method was used to measure OPG and RANKL levels in culture solution. Fluorescence quantitative real-time PCR (FQ-PCR) was used to detect the expression of OPG and RANKL mRNA. After three consecutive passages, more than 95% of the primary synovial cells became long spindle fibroblast-like cells. SABC staining results showed that the fibroblast-like cells were negative for anti-CD68 antibody and positive for anti-vimentin antibody, with brown madder stained. CCK-8 test demonstrated that the absorbance (A) value at 450 nm was significantly lower in IL-6R antibody group than in PMMA group and control group (P<0.01), but there was no statistically significant difference in A value at 450 nm between the control group and PMMA group (P>0.05). Results of ELISA indicated that the expression of OPG was significantly higher in IL-6R antibody group than in PMMA group and control group (P<0.01). The expression of RANKL was inhibited (P<0.05), and the ratio of OPG/RANKL was significantly increased in IL-6R antibody group as compared with PMMA group and control group. There was no significant difference in the expression of OPG between control group and PMMA group (P>0.05), but the expression of RANKL was higher in PMMA group than in control group (P<0.05), and there was a significant difference in the ratio of OPG/RANKL between them (P<0.05). Results of FQ-PCR revealed the expression of RANKL mRNA was significantly inhibited (P<0.01) and the expression of OPG mRNA was significantly increased (P<0.01) in IL-6R antibody group as compared with PMMA group and control group. The expression of RANKL mRNA was higher in PMMA group than in control group (P<0.05), but the expression of OPG mRNA had no significant difference between them (P>0.05). IL-6R antibody could significantly increase the expression of OPG, but inhibit the expression of RANKL, which might provide a theoretical basis of molecular biology for the prevention and treatment of aseptic loosening of prosthesis.

Keywords

interleukin-6 receptor / polymethyl methacrylate / bone cement / synovial fibroblasts / osteoprotegerin / receptor activator of nuclear factor-kappaB ligand

References

[1] MostardiRA, KovacikMW, RamsierRD, et al.. A comparison of the effects of prosthetic and commercially pure metals on retrieved human fibroblasts: the role of surface elemental composition. Acta Biomater, 2010, 6(2): 702-707

[2] ManlapazM, MaloneyWJ, SmithRL. In vitro activation of human fibroblasts by retrieved titanium alloy wear debris. J Orthop Res, 1996, 14(3): 465-472

[3] BeckRT, IllingworthKD, SalehKJ. Review of periprosthetic osteolysis in total joint arthroplasty: an emphasis on host factors and future directions. J Orthop Res, 2012, 30(4): 541-546

[4] PurduePE, KoulouvarisP, NestorBJ, et al.. The central role of wear debris in periprosthetic osteolysis. HSS J, 2006, 2(2): 102-113

[5] Navarro-MillánI, SinghJA, CurtisJR. Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor. Clin Ther, 2012, 34(4): 788-802

[6] TanakaT, KishimotoT. Immunotherapeutic implication of IL-6 blockade. Immunotherapy, 2012, 4(1): 87-105

[7] DayerJM, ChoyE. Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. Rheumatology (Oxford), 2010, 49(1): 15-24

[8] GoodmanSB, LindM, SongY, et al.. In vitro, in vivo, and tissue retrieval studies on particulate debris. Clin Orthop Relat Res, 199825-34

[9] WestbyMD, BackmanCL. Patient and health professional views on rehabilitation practices and outcomes following total hip and knee arthroplasty for osteoarthritis: a focus group study. BMC Health Serv Res, 2010, 10: 119

[10] HallabNJ, JacobsJJ. Biologic effects of implant debris. Bull NYU Hosp Jt Dis, 2009, 67(2): 182-188

[11] KorenyT, Tunyogi-CsapóM, GálI, et al.. The role of fibroblasts and fibroblast-derived factors in periprosthetic osteolysis. Arthritis Rheum, 2006, 54(10): 3221-3232

[12] HoltG, MurnaghanC, ReillyJ, et al.. The biology of aseptic osteolysis. Clin Orthop Relat Res, 2007, 460: 240-252

[13] KnowlesHJ, AthanasouNA. Canonical and non-canonical pathways of osteoclast formation. Histol Histopathol, 2009, 24(3): 337-346

[14] KrauseA, ScalettaN, JiJD, et al.. Rheumatoid arthritis synoviocyte survival is dependent on Stat3. J Immunol, 2002, 169(11): 6610-6616

[15] HeinrichPC, BehrmannI, HaanS, et al.. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J, 2003, 374Pt1: 1-20

[16] BoyceBF, YaoZ, XingL. Functions of nuclear factor kappaB in bone. Ann N Y Acad Sci, 2010, 1192: 367-375

[17] XuJ, WuHF, AngES, et al.. NF-kappaB modulators in osteolytic bone diseases. Cytokine Growth Factor Rev, 2009, 20(1): 7-17

[18] TaoK, ZengH, XiongA, et al.. Regulation of IL-6R antibody on PMMA bone cement mediated mRNA expression of MMPs and vascular factors by synovial fibroblasts. Zhongguo Guzhi Shusong Zazhi (Chinese), 2011, 17(6): 477-483

[19] PivonkaP, ZimakJ, SmithDW, et al.. Theoretical investigation of the role of the RANK-RANKL-OPG system in bone remodeling. J Theor Biol, 2010, 262(2): 306-316

[20] MandelinJ, LiTF, LiljeströmM, et al.. Imbalance of RANKL/RANK/OPG system in interface tissue in loosening of total hip replacement. J Bone Joint Surg Br, 2003, 85(8): 1196-1201

[21] KnowlesHJ, AthanasouNA. Canonical and non-canonical pathways of osteoclast formation. Histol Histopathol, 2009, 24(3): 337-346

[22] CoetzeeM, KrugerMC. Osteoprotegerin-receptor activator of nuclear factor-kappaB ligand ratio: a new approach to osteoporosis treatment?. South Med J, 2004, 97(5): 506-511

[23] HenniganS1, KavanaughA. Interleukin-6 inhibitors in the treatment of rheumatoid arthritis. Ther Clin Risk Manag, 2008, 4(4): 767-775

[24] GenoveseMC, McKayJD, NasonovEL, et al.. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum, 2008, 58(10): 2968-2980

[25] SmolenJS, BeaulieuA, Rubbert-RothA, et al.. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet, 2008, 371(9617): 987-997